2018
Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
Dinan MA, Li Y, Reed SD, Sosa JA. Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population. Endocrine Practice 2018, 25: 31-42. PMID: 30383499, DOI: 10.4158/ep-2018-0253.Peer-Reviewed Original ResearchConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneThyroid-stimulating hormoneMultivariable analysisPatient populationUse of rhTSHLower inpatient costsMean outpatient costsDistant metastatic diseaseDifferentiated thyroid cancerEmergency department visitsRadioactive iodine administrationCancer patient populationSEER-Medicare dataCostly hospital staysTotal inpatient daysHealthcare Common Procedure Coding SystemTotal Medicare paymentsNumber of outpatientsMedicare patient populationPositron emission tomographySimilar overall costsRAI administrationHospital stayMultiple comorbiditiesAdvanced imaging and hospice use in end-of-life cancer care
Dinan MA, Curtis LH, Setoguchi S, Cheung WY. Advanced imaging and hospice use in end-of-life cancer care. Supportive Care In Cancer 2018, 26: 3619-3625. PMID: 29728843, DOI: 10.1007/s00520-018-4223-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanBreast NeoplasmsColorectal NeoplasmsComorbidityDiagnostic ImagingFemaleHospice CareHospicesHumansLung NeoplasmsMaleMedicareMiddle AgedNeoplasmsOutcome Assessment, Health CareProstatic NeoplasmsReferral and ConsultationRetrospective StudiesSEER ProgramTerminal CareUnited StatesConceptsHospital referral regionsHospice enrollmentComputerized tomographyHospice useLife careReferral regionsAdvanced imagingPopulation-based retrospective studyHigh rateLate hospice enrollmentLife cancer careMultivariable logistic regressionSEER-Medicare dataMagnetic resonance imagingPositron emission tomographyEnd of lifeGreater comorbidityReal-world practiceAggressive endBlack patientsMultivariable analysisRetrospective studyResultsA totalStudy criteriaCancer care
2014
Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005. Journal Of Thoracic Oncology 2014, 9: 512-518. PMID: 24736074, DOI: 10.1097/jto.0000000000000102.Peer-Reviewed Original ResearchConceptsCell lung cancerTotal health care costsHealth care costsPositron emission tomographyProportion of patientsRate of surgeryMedicare beneficiariesLung cancerCare costsEmission tomographySurgical resectionInpatient costsRetrospective cohort studyYear of diagnosisMain outcome measuresCohort studyTreatment patternsOutcome measuresRadiation therapyChemotherapyPatientsRadiotherapyStudy periodCancerMedicare approval
2013
Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007. Radiology 2013, 267: 807-817. PMID: 23418003, DOI: 10.1148/radiol.12120174.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositron emission tomographyUse of PETMedicare beneficiariesCases of NSCLCPET useDiagnosis of NSCLCEnd Results-Medicare dataMultivariable logistic regression analysisDuke University Health SystemHalf of patientsCell lung cancerExamination 2 monthsMultivariable regression analysisUniversity Health SystemLogistic regression analysisDemographic subgroupsRegression analysisInstitutional review boardNonblack patientsPrimary outcomeFinal cohortSurveillance EpidemiologyLung cancerRetrospective analysis
2012
Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003. Journal Of Clinical Oncology 2012, 30: 2725-2730. PMID: 22753917, DOI: 10.1200/jco.2011.40.4392.Peer-Reviewed Original ResearchConceptsPositron emission tomographyOverall survivalStage migrationMedicare beneficiariesAdvanced diseasePET useEnd Results-Medicare dataEmission tomographyProportion of patientsStage IV diseaseCell lung cancerSelection biasUpstaging of diseaseGreater overall survivalStage-specific survivalStudy criteriaLung cancerSurvival AssociatedImproved outcomesRetrospective analysisStage distributionNSCLCPatientsDiseaseSurvival
2010
Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006
Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA. Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006. JAMA 2010, 303: 1625-1631. PMID: 20424253, DOI: 10.1001/jama.2010.460.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaLung cancerMedicare beneficiariesBreast cancerCancer typesColorectal cancerProstate cancerImaging costsPositron emission tomography scanIncident breast cancerYear of diagnosisEmission tomography scanBone density studiesMean total costMagnetic resonance imagingPositron emission tomographyBone scanTreatment patternsIncident casesCancer careHalf of beneficiariesTomography scanUS CentersMean annual increaseResonance imaging